Clearmind Medicine (CSE: CMND) has announced positive pre-clinical results for its innovative psychedelic molecule MEAI treatment for cocaine addiction. MEAI is the company’s primary therapeutic, known for its low toxicity, strong safety profile, and absence of side effects. A recent study indicated that MEAI could help eliminate cocaine-induced conditioned place preference and cravings without causing addiction. The study found that a 5mg/kg dose was the most effective and will be further investigated.
Chief executive officer of Clearmind, Dr. Adi Zuloff-Shani, expressed confidence in the potential of MEAI to address cocaine addiction based on these findings. He emphasized the importance of developing new and effective therapeutics in a field where current treatment options are limited.
The pre-clinical trial, led by Professor Gal Yadid and the team at the Gonda Multidisciplinary Brain Research Centre, utilized the conditioned place preference model with animals that were trained to self-administer cocaine. Results showed a responsive sub-group that exhibited decreased cravings when treated with MEAI, highlighting the compound’s potential for addressing cocaine addiction.
Clearmind holds patents for MEAI, a non-hallucinogenic compound, and is dedicated to discovering safe and innovative psychedelic-derived therapeutics. Based in Vancouver, the biotech company focuses on developing treatments for alcohol use disorder and other health challenges, including cocaine addiction.
